Vectura has announced that revenues from inhaled drugs rose 7.1% in the first half of 2018, with Flutiform revenues up 3.1% compared to the first half of 2017 and up 6.1% compared to the second half of 2017. Total revenue for the six months was up 1.4%.
The company also said that results from Phase 2 studies of VR647 nebulized budesonide inhalation suspension support advancement of that program to Phase 3 and that results from a Phase 3 study of VR475 nebulized budesonide are expected by the end of the year.
According to Vectura, Hikma plans to submit data regarding the VR315 salmeterol/fluticasone DPI to the FDA in 2019. Hikma received a complete response letter to its NDA for VR315 in May 2017, and in March 2018, Hikma announced that the FDA requested an additional clinical trial.
Vectura also reported “good progress being made in strategic partnering discussions” regarding products based on its open-inhale-close DPI.
Read the Vectura press release.
